The Development of a System for Measurement of Tremor
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05956223 |
Recruitment Status :
Not yet recruiting
First Posted : July 21, 2023
Last Update Posted : July 21, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Essential Tremor Dystonia | Device: Virtual Reality measurement of essential tremor and dystonia | Not Applicable |
This study aims to develop a way of objectively measuring the neurological disorders, Essential Tremor (ET) and Dystonia. These conditions can affect the upper and lower limbs, head, voice, face and trunk. ET and dystonia can be difficult to assess and treat, particularly if severe, and therapies are limited. Currently the severity of these conditions is formally assessed by clinician rated scales such as the Essential Tremor Rating Assessment Scale (TETRAS) which is biased towards the upper limbs, requires training and is not objective. There is a need for a more precise, less variable measure of tremor that can used easily be non-expert clinicians. This study questions whether it is possible to quantify ET and dystonia using a measurement system in a virtual reality (VR) environment.
We will collect data from measurement sensors embedded in the VR environment from control, ET and dystonic participants by placing them in a VR environment and instructing them to perform the TETRAS. This will help us to develop an algorithm which can measure ET severity using machine learning. We expect that the algorithm will provide a better assessment of ET and dystonia than the TETRAS.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 120 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | The Development of a System for Measurement of Tremor |
Estimated Study Start Date : | July 30, 2023 |
Estimated Primary Completion Date : | June 30, 2025 |
Estimated Study Completion Date : | June 30, 2025 |

Arm | Intervention/treatment |
---|---|
Stage 1 Controls
Control participants - healthy volunteers without a known neurological disorder
|
Device: Virtual Reality measurement of essential tremor and dystonia
|
Experimental: Stage 2 Patients with Essential Tremor
Participants with moderately severe essential tremor
|
Device: Virtual Reality measurement of essential tremor and dystonia
|
Experimental: Stage 3 Patients with Essential Tremor of varying severities
Participants with essential tremor ranging from just detectable by neurologist to severe.
|
Device: Virtual Reality measurement of essential tremor and dystonia
|
Experimental: Stage 5
Participants with essential tremor and dystonia of the upper limbs, head and neck
|
Device: Virtual Reality measurement of essential tremor and dystonia
|
- TETRAS scores [ Time Frame: up to 4 weeks ]The TETRAS has 16 tasks each rated from 1 to 4 with 64 maximum points, with a score of 1 denoting a minimal or barely noticeable tremor and 4 denoting a severe tremor. Scoring for the head provides 8 points; the voice and lower limbs 4 points each; and the upper limb each obtains 20 points, with an extra 4 points for handwriting and 4 for postural tremor.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria - Control participants
- Aged 18 to 80 years
- Able to provide informed consent for self
- Able to comply with all study procedures
Exclusion Criteria -Control participants
- Any neurological disorder
- Any other non-neurological cause of tremor e.g. medication induced
Inclusion Criteria - ET participants
- Aged 18 to 80 years
- Able to provide informed consent for self
- Clinical diagnosis of ET or ET plus syndrome
- Able to comply with all study procedures
Exclusion Criteria - ET Participants
- Tremor other than ET (e.g. parkinsonian, functional tremor)
- Presence of other movement disorder
- For DBS participants: willingness to turn off their IDU (deep brain stimulator battery) temporarily switched off during their assessment. Participants must have their own ability to turn this back on following the assessment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05956223
Contact: Sarah Osborn | +61428051052 | sarah.osborn@unimelb.edu.au |
Australia, Victoria | |
The Royal Victorina Eye and Ear Hospital | |
East Melbourne, Victoria, Australia, 3002 | |
Contact: Sarah Osborn +61428051052 sarah.osborn@unimelb.edu.au |
Principal Investigator: | David R Szmulewicz | The Royal Victorian Eye and Ear Hospital |
Responsible Party: | Peter Keller, Associate Professor, Royal Victoria Eye and Ear Hospital |
ClinicalTrials.gov Identifier: | NCT05956223 |
Other Study ID Numbers: |
23-1562H |
First Posted: | July 21, 2023 Key Record Dates |
Last Update Posted: | July 21, 2023 |
Last Verified: | July 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Dystonia Tremor Essential Tremor Dyskinesias |
Neurologic Manifestations Nervous System Diseases Movement Disorders Central Nervous System Diseases |